Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 4/20 | 0.70 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | PDE8A | O60658 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30332108 | 0.93 | YTHDC1 (0.60) | YTHDC1CNR2P2RX7PDE8ALMNA | |
| SCHEMBL3441063 | 0.86 | YTHDC1 (0.67) | YTHDC1CNR2PDE8ALMNATP53 | |
| SCHEMBL2195860 | 0.86 | YTHDC1 (0.54) | YTHDC1P2RX7PDE8ALMNATP53 | |
| SCHEMBL27388471 | 0.83 | YTHDC1 (1.00) | YTHDC1 | |
| SCHEMBL336202 | 0.81 | YTHDC1 (0.49) | YTHDC1P2RX7PDE8ALMNATP53 | |
| SCHEMBL31329164 | 0.79 | YTHDC1 (0.46) | YTHDC1P2RX7PDE8ALMNATP53 | |
| SCHEMBL2911823 | 0.78 | HSP90AA1 (0.51) | YTHDC1 | |
| SCHEMBL20105702 | 0.77 | YTHDC1 (0.50) | YTHDC1CNR2PDE8ALMNAGRM1 | |
| SCHEMBL12537437 | 0.75 | YTHDC1 (0.46) | YTHDC1P2RX7 | |
| SCHEMBL30584024 | 0.75 | ADORA2A (0.50) | YTHDC1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1456209-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1456209-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | YTHDC1 2858/4885CNR2 103/4885P2RX7 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.